X
API Suppliers
0
US DMFs Filed
0
CEP/COS Certifications
0
JDMFs Filed
0
Other Certificates
0
Other Suppliers
0
0
0
USA (Orange Book)
0
Europe
Canada
0
Australia
0
South Africa
0
Uploaded Dossiers
0
U.S. Medicaid
0
Annual Reports
0
https://pink.pharmaintelligence.informa.com/PS142810/GSKs-Trelegy-Ellipta-US-FDA-Panel-To-Weigh-Role-Of-Inhaled-Corticosteroids-On-Mortality-Results
https://www.cnbc.com/2019/12/31/reuters-america-exclusive-drugmakers-from-pfizer-to-gsk-to-hike-u-s-prices-on-over-200-drugs.html
https://www.reuters.com/article/us-astrazeneca-fda/astrazenecas-combo-lung-disease-therapy-fails-to-win-fda-approval-idUSKBN1WG2XH
https://www.biopharmadive.com/news/astrazeneca-pt010-fda-rejection-copd-gsk-respiratory-competition/564090/
https://www.fiercepharma.com/pharma/gsk-s-trelegy-shows-promise-asthma-despite-mixed-results-phase-3-trial
https://www.businesswire.com/news/home/20190502005658/en/Phase-III-CAPTAIN-Study-Trelegy-Ellipta-Patients/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.businesswire.com/news/home/20190502005658/en/Phase-III-CAPTAIN-Study-Trelegy-Ellipta-Patients/?feedref=JjAwJuNHiystnCoBq_hl-QyNsUQ29c24MKpwrFSKUOTZQK86VRF04E6aMvZHPoaH7fxFuNFTHSunhvli30RlBNXya2izy9YOgHlBiZQk2LP6oD-t3eB0qV-nJQ-WeFyCEq7XOd8em_Uy42DWNTo2Mw==
https://www.fiercepharma.com/pharma/teva-s-shaved-2-5b-costs-out-3b-goal-seeks-2020-growth
https://www.fiercepharma.com/manufacturing/glaxosmithkline-opens-expanded-api-production-for-copd-inhalers
https://www.gsk.com/en-gb/media/press-releases/gsk-submits-regulatory-application-in-japan-for-once-daily-single-inhaler-triple-therapy-ffumecvi-for-patients-with-copd/
http://www.pharmatimes.com/news/us_clears_paediatric_use_of_gsks_arnuity_ellipta_1236328
http://www.pharmatimes.com/news/gskinnovivas_trelegy_ellipta_wins_expanded_nod_for_copd_1233174
http://www.pharmatimes.com/news/gsk_reports_q1_sales_decline_1233206
http://investor.inva.com/news-releases/news-release-details/once-daily-trelegy-ellipta-gains-expanded-indication-us
https://www.gsk.com/en-gb/media/press-releases/landmark-impact-study-published-in-nejm-shows-significant-benefits-of-trelegy-ellipta-for-patients-with-copd/
http://www.pharmatimes.com/news/eu_expands_scope_of_gskinnovivas_asthma_inhaler_1226718
https://www.dddmag.com/news/2018/03/positive-eu-approval-labeling-update-gsks-relvar-ellipta
http://www.pharmatimes.com/news/gsk,_innovivas_trelegy_ellipta_cleared_for_copd_1211588
https://www.reuters.com/article/us-gsk-lung/europe-approves-glaxosmithklines-new-triple-lung-drug-idUSKBN1DG0UZ
http://www.nasdaq.com/article/theravance-shares-rise-on-approval-of-glaxos-copd-therapy-cm879527
http://www.reuters.com/article/us-gsk-copd-approval/gsks-three-in-one-inhaler-gets-positive-opinion-from-eu-agency-idUSKCN1BQ0M0
https://www.biospectrumasia.com/news/27/9388/gsk-and-propeller-expand-digital-health-collaboration.html
http://www.pharmatimes.com/news/gsk_files_for_extended_use_of_relvar_ellipta_in_asthma_1199116
http://www.pharmatimes.com/news/gsks_inhaler_improves_asthma_control_in_real_world_study_1192433
http://cphi-online.com/propeller-health-announces-development-agreement-news038205.html
http://www.marketwatch.com/story/regulatory-update-gsk-and-theravance-announce-intention-to-file-relvarr-elliptar-for-copd-in-japan-2015-09-24
http://www.fiercepharmamanufacturing.com/story/gsk-resumes-production-plant-where-legionella-bacteria-was-detected/2015-08-18
http://www.bloomberg.com/news/articles/2015-05-05/prescription-for-glaxo-a-new-boss-
http://images.info.science.thomsonreuters.biz/Web/ThomsonReutersScience/%7B7e677448-1313-40ae-9978-6be1a8532a08%7D_A4_MarketInsight_Report_0213_012__edits_2.pdf
http://www.bloomberg.com/news/articles/2015-03-17/gsk-theravance-s-breo-faces-scrutiny-over-safety-for-asthma
Market Place
Share 
